Responses

PDF
Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Intravitreal chemotherapy in non-vitreal retinoblastoma
    • Tero T. Kivelä, Professor and Chair University of Helsinki and Helsinki University Hospital
    • Other Contributors:
      • Sebastian Eskelin, Consultant Ophthalmologist

    In their report, entitled “Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds“, Abramson and corkers report on the successful use of intravitreal chemotherapy in 52 patients for subretinal seeds and recurrent retinal tumours [1]. They state that, prior to their experience, intravitreal chemotherapy had been used exclusively to control persistent or recurrent vitreous seeding in retinoblastoma that had been refractory to systemic intravenous or intra-arterial chemotherapy.

    In fact, intravitreal chemotherapy as an adjuvant treatment for both subretinal seeds and recurrent retinal tumours, including its use instead of systemic chemotherapy in the setting of chemothermotherapy for small unresponsive primary retinoblastomas, has been in regular use already for a decade at the Ocular Oncology Service, Helsinki University Eye Hospital. Indeed, three of the first four patients that we reported during the congress of the International Society of Ocular Oncology in 2009 [2], and published in 2011 [3], received intravitreal methotrexate for reasons other than vitreous seeds. Subsequent experience with intravitreal chemotherapy with methotrexate and, later, with melphalan has strengthened our initial findings, as does the comprehensive report of Abramson and coworkers.

    1. Abramson DH, Ji X, Francis JH, et al. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds. Br J Ophthalmol 2018 Jun 6. pii: bjophthalmol-...

    Show More
    Conflict of Interest:
    None declared.